7:19AM On the Wires : Seattle Genetics (SGEN) announced that it has expanded its antibody-drug conjugate collaboration agreement with Genentech, a member of the Roche Group (RHHBY). Under the expanded agreement, Genentech will pay an upfront fee of $12 mln for rights to utilize Seattle Genetics' ADC technology with additional antigens to be named by Genentech
Market Data 
Markets 
AI
